Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.30 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10217171 | 0.81 | — | — | |
| SCHEMBL17198902 | 0.71 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL85822 | 0.69 | NOS3 (0.31) | — | |
| SCHEMBL768751 | 0.69 | — | — | |
| SCHEMBL26151613 | 0.68 | GABRA2 (0.33) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL21924845 | 0.67 | — | — | |
| SCHEMBL20375479 | 0.67 | — | — | |
| SCHEMBL24525054 | 0.67 | SMARCA2 (0.35) | SMARCA2SMARCA4 | |
| SCHEMBL21722751 | 0.67 | CA2 (0.40) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL26739791 | 0.67 | SMARCA2 (0.41) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2017-01-19 | — | — | US | disclosed |
| US-9533991-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031891-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | CYP3A4 3750/4885CYP2D6 2447/4885TSHR 2395/4885 |
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | CYP3A4 4535/4885CYP2D6 4440/4885TSHR 120/4885 |
| US-20170015671-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, SYK | CYP3A4 3750/4885CYP2D6 2447/4885TSHR 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.